The price of Vyvanse tablets can vary depending on factors such as dosage, quantity, and insurance coverage. For instance, a 30-count prescription of 20mg Vyvanse capsules might cost around $300-$400 without insurance. However, with insurance, the out-of-pocket cost could be significantly lower, often falling between $20-$60 for a 30-day supply [1].
How much does a 30-day supply of Vyvanse cost?
A 30-day supply of Vyvanse can range from approximately $300 to over $400 when purchased without insurance. Factors influencing this cost include the specific dosage strength and the number of capsules or tablets prescribed. Insurance plans can substantially reduce this cost, with co-pays often ranging from $20 to $60 for a month's supply.
What are the costs of different Vyvanse dosages?
The price of Vyvanse is directly related to its dosage strength. Higher dosages, such as 70mg, will generally cost more than lower dosages, like 20mg, for the same quantity. For example, a 30-count prescription of 70mg Vyvanse capsules could exceed $400 without insurance, while a similar quantity of 20mg capsules might be in the $300-$400 range. Patient assistance programs and discount cards can help mitigate these costs.
Are there ways to get Vyvanse at a lower price?
Several avenues can help reduce the cost of Vyvanse. Takeda, the manufacturer of Vyvanse, offers a savings card for eligible commercially insured patients that can lower co-pays [1]. Additionally, looking into prescription discount cards or comparing prices at different pharmacies can yield savings. For uninsured or underinsured patients, exploring patient assistance programs may provide further cost relief.
When does Vyvanse's patent expire?
The primary patents protecting Vyvanse (lisdexamfetamine dimesylate) are set to expire in the coming years. For instance, key patents are expected to expire around 2023 and 2025 [2]. The exact timing of patent expiry can be complex due to various patent types and potential extensions.
Can generic versions of Vyvanse be available after patent expiry?
Following the expiration of primary patents, generic versions of Vyvanse may become available. The introduction of generic alternatives typically leads to a significant decrease in drug prices. The availability and pricing of generics depend on the regulatory approval process by agencies like the FDA and market dynamics. DrugPatentWatch.com tracks patent expiries and potential generic entry for numerous drugs, including Vyvanse [2].
What is the mechanism of action for Vyvanse?
Vyvanse is a central nervous system stimulant. It is a prodrug of dextroamphetamine, meaning it is converted into its active form in the body. Dextroamphetamine works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. These neurotransmitters play a role in attention and impulse control.
Sources:
[1] https://www.takeda.com/en-us/patients-and-communities/patients/patient-support-programs/vyvanse-savings-card/
[2] https://drugpatentwatch.com/